Serum-Based DNA Methylation Biomarkers in Colorectal Cancer: Potential for Screening and Early Detection
Thomas A. Summers, Russell Charles Langan, Aviram Nissan, Björn L.D.M. Brücher, Anton J. Bilchik, Mladjan Protić, Martin Däumer, Itzhak Avital, Alexander Stojadinovic · Journal of Cancer · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2013
Abstract
Colorectal cancer (CRC) is the third most common cause of cancer-related death in the United States. Early identification and treatment of pre-cancerous colorectal lesions, or node-negative CRC are highly effective interventions that substantially reduce disease-specific mortality. Colonoscopy remains a highly effective primary screening tool based on its excellent diagnostic accuracy, and its ability to remove pre-cancerous lesions. However, the nature of the procedure limits compliance with colonoscopy intended for population-based CRC screening.
A significant advance in the screening and care of these patients could be realized by blood-based biomarkers, which could accurately identify patients at-risk for CRC development whom might benefit from early and/or more frequent surveillance for disease. We reviewed and herein discuss the potential for serum based DNA methylation biomarkers for screening and early detection of CRC.
Open the resolved locator · 10.7150/jca.5839
Metadata licence: OpenAlex metadata (CC0)